BioHarvest Sciences Q1 Earnings Call Highlights

Key Points

• Interested successful BioHarvest Sciences Inc.? Here are 5 stocks we similar better.

• BioHarvest Sciences reported first-quarter gross of $8.5 million, up 8% twelvemonth implicit year, and kept its 2026 guidance unchanged for some the D2C and CDMO businesses. Cash and deposits roseate sharply to $20.2 million from $3.4 cardinal a twelvemonth earlier.

• The institution is reorganizing astir a two-business structure: the VINIA direct-to-consumer conception and the CDMO platform. Management said this should amended superior allocation and execution, portion besides preparing for a caller manufacturing installation expected to statesman accumulation successful 2H 2027.

• BioHarvest highlighted CDMO advancement successful fragrance and saffron, including a $1.2 cardinal signifier 2 fragrance declaration and completion of saffron signifier 1. Management besides said it expects much CDMO projects up and remains focused connected a selling reset for VINIA to amended lawsuit acquisition efficiency.

BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter gross and reiterated its 2026 outlook arsenic absorption elaborate a broader reorganization astir 2 concern lines: its direct-to-consumer VINIA products concern and its declaration improvement and manufacturing organization, oregon CDMO, platform.

The works compartment civilization biotechnology institution said gross for the archetypal 4th of 2026 roseate 8% twelvemonth implicit twelvemonth to $8.5 million, compared with $7.9 cardinal successful the prior-year period. Gross nett accrued to $5 million, oregon 59% of revenue, from $4.6 million, oregon 58% of revenue, a twelvemonth earlier.

→ Rocket Lab Just Hit a New All-Time High—Time to Buy oregon Let It Breathe?

Net nonaccomplishment widened to $2.6 million, oregon $0.11 per basal and diluted share, compared with a nett nonaccomplishment of $2.3 million, oregon $0.13 per basal and diluted share, successful the aforesaid 4th past year. Adjusted EBITDA loss, a non-IFRS measure, was $1.2 million, successful enactment with the year-earlier period.

Cash and currency equivalents, unneurotic with slope deposits, totaled $20.2 cardinal arsenic of March 31, 2026, up from $3.4 cardinal arsenic of March 31, 2025.

Company Emphasizes Two-Business Structure

→ MP Materials Is Quietly Building a Rare Earth Powerhouse

Chief Executive Officer Zaki Rakib said BioHarvest is present managing the institution done a “two-lens” framework, separating the operating presumption of its D2C products concern from its CDMO services division. Rakib said the attack is intended to amended performance, superior allocation and execution.

Under that framework, the institution reported an adjusted EBITDA nonaccomplishment of $904,000 for the CDMO services part and $286,000 for the products part successful the archetypal quarter. In the year-ago quarter, those losses were $953,000 and $235,000, respectively.